妇科肿瘤患者血清精子蛋白17的检测及其临床意义

Detection of sperm protein 17 in serum and its significance in patients with gynecology cancer

目的定量测定妇科肿瘤患者血清精子蛋白17(Sp17)的水平,以了解Sp17是否适合作为妇科肿瘤诊断的血清学标志。方法利用125I标记重组Sp17蛋白,建立放射免疫分析方法,测定正常人(59例)和妇科肿瘤患者(22例,其中卵巢癌14例,子宫内膜癌8例)血清Sp17的含量,并与妇科肿瘤组织Sp17的表达情况进行比较。结果正常人血清Sp17水平为(15.6±7.66)μg/L,显著低于妇科恶性肿瘤患者血清Sp17水平(64.36±34.44)μg/L。以大于30.92μg/L为临界值,22例妇科恶性肿瘤患者中9例(40.9%)Sp17为阳性。免疫组化检测22例中12例(54.5%)阳性。结论妇科肿瘤患者血清Sp17含量显著高于正常人,但肿瘤患者血清Sp17水平与肿瘤组织Sp17表达无显著相关性。

Objective To quantify the level of human sperm protein 17 （Sp17） in serum of the healthy and patients with gynecological cancers and to evaluate whether Sp17 is a suitable serum marker for the diagnosis of gynecological cancers. Methods The recombinant human Sp17 was radioiodinated by the chloramine T method, 125 I-rhSp17 was used to develop a radioimmunoassay to determine Sp17 in serum of the healthy and the patients, Meanwhile, Sp17 levels in serum were compared with the expression of Sp17 in tissues from gynecological cancers. Results The level of serum Sp17 was （ 15.60 ±7.66 ）μg/L in healthy subjects（ n = 59 ） ,which was significantly lower than those in twenty-two patients （64.36 ± 34.44）μg/L. Sera from nine of twenty-two patients（40.9% ） were positive for Sp17 by radioimmunoassay assay. Tumor tissues from twelve of twenty-two patients （54.5%） were positive for Spl 7 by immunohistochemist17 assay. Conclusions Markedly elevated serum levels of Sp17 were found in patients with gynecological cancers. However,there was no significant correlation between serum level of Sp17 and expression of Sp17 in tumor tissues in patients with gynecological cancer.